Pharmaceutical giant Novartis plans to add a new manufacturing facility in Morrisville, expanding its footprint in North Carolina as part of a broader push to strengthen U.S.-based drug production.
The company announced Thursday it will build a 56,200-square-foot active pharmaceutical ingredient manufacturing facility focused on producing materials used in solid dosage tablets, capsules and RNA therapeutics. Novartis says the new site will help strengthen end-to-end manufacturing in the United States, from active ingredients through finished medicines.
The Morrisville project will mark Novartis’ seventh new facility announced within a year, following the company’s $23 billion investment plan aimed at expanding U.S.-based manufacturing and research and development. With the addition of the new site, Novartis will operate five facilities across three locations in North Carolina…